Insiders at the company have transacted a total of 12 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 415,269 shares. Insider sales of the common stock occurred on 6 occasions, with total insider shares sold totaling 890,178 shares.
The company’s stock has a 5-day price change of 55.37% and 172.19% over the past three months. KURA shares are trading 44.99% year to date (YTD), with the 12-month market performance up to 52.86% higher. It has a 12-month low price of $7.41 and touched a high of $21.40 over the same period. KURA has an average intraday trading volume of 1.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 33.20%, 61.52%, and 89.02% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Kura Oncology Inc (NASDAQ: KURA) shares accounts for 91.30% of the company’s 68.31M shares outstanding.
It has a market capitalization of $1.55B and a beta (3y monthly) value of 0.87. The earnings-per-share (ttm) stands at -$2.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.70% over the week and 7.12% over the month.
Analysts forecast that Kura Oncology Inc (KURA) will achieve an EPS of $Global X Uranium ETF for the current quarter, $30.55 for the next quarter and $ETF for Type. The lowest estimate earnings-per-share for the quarter is $Kintara Therapeutics, Inc. while analysts give the company a high EPS estimate of $Kura Sushi USA, Inc. Comparatively, EPS for the current quarter was $Zura Bio Limited a year ago. Earnings per share for the fiscal year are expected to decrease by -2.15%, and -9.95% over the next financial year. EPS should grow at an annualized rate of 19.93% over the next five years, compared to -5.93% over the past 5-year period.
Looking at the support for the KURA, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on December 22, 2023, with the firm’s price target at $26.
